Michael B Atkins1, Ahmad Tarhini2, Michael Rael3, Komal Gupte-Singh4, Elliott O'Brien3, Corey Ritchings4, Sumati Rao4, David F McDermott5. 1. Georgetown Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA. 2. Center for Immuno-Oncology Research, Cleveland Clinic, Cleveland, OH 44106, USA. 3. Evidera, Inc., San Francisco, CA 94111, USA. 4. Bristol-Myers Squibb, Princeton, NJ 08540, USA. 5. Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Abstract
AIM: Comparison of clinical outcomes of nivolumab + ipilimumab versus BRAF + MEK inhibitors (dabrafenib + trametinib or vemurafenib + cobimetinib) in BRAF-mutant advanced melanoma. METHODS: Matching-adjusted indirect comparisons were conducted between nivolumab + ipilimumab (CheckMate 067/069 studies) and BRAF + MEK inhibitors (COMBI-d, COMBI-v and coBRIM studies). Overall survival (OS), progression-free survival and objective response rates were assessed. RESULTS: After adjusting, nivolumab + ipilimumab showed improved OS versus dabrafenib + trametinib (hazard ratio [HR] = 0.64; 95% CI: 0.46-0.89) or vemurafenib + cobimetinib (HR = 0.56; 95% CI: 0.36-0.89); OS outcomes were similar at 1 year, with benefits emerging after 12 months; progression-free survival and objective response rates were similar. Grade 3/4 adverse events occurred in 54.1% with nivolumab + ipilimumab, 31.6% with dabrafenib + trametinib and 59.5% with vemurafenib + cobimetinib. CONCLUSION: Nivolumab + ipilimumab had significantly improved clinical outcomes versus BRAF + MEK inhibitors, with benefits increasing after longer follow-up. Ongoing randomized trials directly comparing these treatments are necessary to prospectively validate these findings.
AIM: Comparison of clinical outcomes of nivolumab + ipilimumab versus BRAF + MEK inhibitors (dabrafenib + trametinib or vemurafenib + cobimetinib) in BRAF-mutant advanced melanoma. METHODS: Matching-adjusted indirect comparisons were conducted between nivolumab + ipilimumab (CheckMate 067/069 studies) and BRAF + MEK inhibitors (COMBI-d, COMBI-v and coBRIM studies). Overall survival (OS), progression-free survival and objective response rates were assessed. RESULTS: After adjusting, nivolumab + ipilimumab showed improved OS versus dabrafenib + trametinib (hazard ratio [HR] = 0.64; 95% CI: 0.46-0.89) or vemurafenib + cobimetinib (HR = 0.56; 95% CI: 0.36-0.89); OS outcomes were similar at 1 year, with benefits emerging after 12 months; progression-free survival and objective response rates were similar. Grade 3/4 adverse events occurred in 54.1% with nivolumab + ipilimumab, 31.6% with dabrafenib + trametinib and 59.5% with vemurafenib + cobimetinib. CONCLUSION:Nivolumab + ipilimumab had significantly improved clinical outcomes versus BRAF + MEK inhibitors, with benefits increasing after longer follow-up. Ongoing randomized trials directly comparing these treatments are necessary to prospectively validate these findings.
Authors: Olivier Michielin; Michael B Atkins; Henry B Koon; Reinhard Dummer; Paolo Antonio Ascierto Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751
Authors: Tao Ouyang; Yanyan Cao; Xuefeng Kan; Lei Chen; Yanqiao Ren; Tao Sun; Liangliang Yan; Bin Xiong; Bin Liang; Chuansheng Zheng Journal: Front Oncol Date: 2021-05-11 Impact factor: 6.244